Loading
A phase 2 trial of Fludarabine, Busulfan and Clofarabine in Acute myeloid leukaemia, run by Nantes University Hospital, now recruiting.
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT is a phase 2 interventional study registered as NCT05917405 by Nantes University Hospital, with 302 participants planned, started 2023-09-14 and due to reach its primary completion in 2028-09-14. Interventions recorded: Fludarabine, Busulfan, ATG, Clofarabine. Conditions recorded: Acute Myeloid Leukemia in Remission.
Linked to the drug Clofarabine because the registry names it among its interventions and Acute myeloid leukaemia among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Clofarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Busulfan, Acute myeloid leukaemia and the tag pipeline.
Shares Fludarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Fludarabine and the tag pipeline.
Shares Fludarabine and the tag pipeline.
Shares Fludarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Fludarabine and the tag pipeline.
Shares Fludarabine, Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/